Shanghai, China, 18 May 2025 — The Minos™ Abdominal Aortic Stent Graft and Delivery System (Minos™), developed by MicroPort® Endovastec™, recently received CE MDR (Medical Device Regulation (EU) 2017/745) certification and market approval in Egypt - a milestone in its global market expansion.
Minos™ was previously certified under the former CE MDD (Medical Device Directive 93/42/EEC). Designed for endovascular treatment of abdominal aortic aneurysms with a proximal neck length ≥15 mm, Minos™ offers strong performance in complex anatomies, including short or angulated necks and narrowed or tortuous access vessels. The device is currently in clinical use across 25 countries.
MicroPort® Endovastec™ remains committed to advancing its globalization strategy by delivering high-quality, innovative products to more countries, enhancing access and improving outcomes for patients with aortic and peripheral vascular diseases worldwide.
About MicroPort® Endovastec™
Founded in 2012, MicroPort® Endovastec™ (Shanghai MicroPort Endovascular MedTech Group Co., Ltd.; SSE: 688016), an associated company of MicroPort® (MicroPort Scientific Corporation; HKEX: 00853), is a global medical device company focusing on R&D, manufacturing, and commercialization of aortic and peripheral vascular interventional devices. MicroPort® Endovastec™'s product portfolio includes thoracic and abdominal aortic stent grafts, stent grafts in surgical operation, peripheral vascular stents, and drug-coated PTA balloon catheters. MicroPort® Endovastec™ breaks barriers and accelerates innovation to provide trustworthy and universal access to state-of-the-art solutions for prolonging and reshaping all lives, and to build a leading enterprise of emerging technologies in great vessel surgery and peripheral vascular medicine.
More information is available at: www.endovastec.com/en